Prolonged treatment for acute symptomatic refractory status epilepticus: outcome in children.
High-dose suppressive therapy (HDST) is used to treat refractory status epilepticus (RSE). Prolonged therapy is required in some cases, and prognosis is important in making therapeutic decisions. The authors therefore studied the long-term outcome in previously normal children who survived prolonged HDST for acute symptomatic RSE. All have intractable epilepsy, and none returned to baseline.
Sahin
Mustafa
M
Division of Epilepsy and Clinical Neurophysiology and the Critical Care Neurology Service, Department of Neurology, Children's Hospital, Boston, MA 02115, USA.
Menache
Caroline C
CC
Holmes
Gregory L
GL
Riviello
James J
JJ
D000208:Acute Disease; D000293:Adolescent; D000927:Anticonvulsants / Q000627:therapeutic use*; D001706:Biopsy; D001921:Brain / Q000187:drug effects / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D002658:Developmental Disabilities / Q000209:etiology; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D004569:Electroencephalography; D004660:Encephalitis / Q000150:complications / Q000175:diagnosis / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D011379:Prognosis; D013226:Status Epilepticus / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome
D000927:Anticonvulsants